Previous Article | Next Article ![]()
Journal of Virology, June 1999, p. 5043-5055, Vol. 73, No. 6
Institute for Virology, Johannes Gutenberg
University, Mainz, Germany
Received 4 January 1999/Accepted 11 March 1999
Transcription of the major immediate-early (MIE) genes of
cytomegaloviruses (CMV) is driven by a strong promoter-enhancer (MIEPE)
complex. Transactivator proteins encoded by these MIE genes are
essential for productive infection. Accordingly, the MIEPE is a crucial
control point, and its regulation by activators and repressors is
pertinent to virus replication. Since the MIEPE contains multiple
regulatory elements, it was reasonable to assume that specific sequence
motifs are irreplaceable for specifying the cell-type tropism and
replication pattern. Recent work on murine CMV infectivity (A. Angulo,
M. Messerle, U. H. Koszinowski, and P. Ghazal, J. Virol.
72:8502-8509, 1998) has documented the proposed enhancing function of
the enhancer in that its resection or its replacement by a
nonregulatory stuffer sequence resulted in a significant reduction of
infectivity, even though replication competence was maintained by a
basal activity of the spared authentic MIE promoter. Notably, full
capacity for productive in vitro infection of fibroblasts was restored
in recombinant viruses by the human CMV enhancer. Using two-color in
situ hybridization with MIEPE-specific polynucleotide probes, we
demonstrated that a murine CMV recombinant in which the complete murine
CMV MIEPE is replaced by the paralogous human CMV core promoter and
enhancer (recombinant virus mCMVhMIEPE) retained the potential to
replicate in vivo in all tissues relevant to CMV disease. Notably,
mCMVhMIEPE was also found to replicate in the liver, a site at which
transgenic hCMV MIEPE is silenced. We conclude that productive in vivo
infection with murine CMV does not strictly depend on a MIEPE
type-specific regulation.
The enhancers of the various
species-specific strains of cytomegaloviruses (CMV), such as those
of human CMV (hCMV) (7), simian CMV (9), rat CMV
(42), and murine CMV (mCMV) (11), are regarded as
important regulatory elements enforcing transcription of the major
immediate-early (MIE) genes that specify transactivator proteins
essential for initiating the productive viral cycle in permissive cell
types. Thus, the enhancer serves primarily as a genetic amplifier of
productive infection. In the specific case of mCMV, the enhancer
operates bidirectionally in that it governs the MIE promoter (MIEP) of
the ie1-ie3 (hereafter shortened to ie1/3)
transcription unit (17), which encodes the principal early
gene transactivator IE3 (28) and the cotransactivator IE1
(18, 19), as well as the promoter of gene ie2,
which is located upstream of ie1/3, is transcribed in
opposite orientation, and encodes the protein murine IE2
(30), for which a critical function has yet to be defined
(8). Notably, murine IE2 has no direct counterpart in hCMV,
whereas murine IE1 and IE3 are the functional analogs of human IE1 and
IE2, respectively. Likewise, the hCMV enhancer controls the hCMV MIEP
of the ie1-ie2 transcription unit, and as is the case for
murine IE1 and IE3, human IE1 and IE2 are derived from respective mRNAs
generated by differential splicing (for reviews, see references
43 and 45). As we have shown
recently for mCMV latency and recurrence in the lungs, MIEP activity
does not inevitably initiate the productive cycle. Specifically, during
latency, focal and stochastic MIEP activity in lung tissue was found to
selectively generate spliced ie1 transcripts, while spliced
transactivator-specifying ie3 transcripts were missing (21). Although these data indicated a role for
posttranscriptional splicing regulation as a second checkpoint in the
initiation of productive infection, MIEP activity is unquestionably the
first condition for productive primary or recurrent infection. Hence, regulation of MIEP activity by the enhancer and regulation of the
enhancer by cellular transcription factors are pertinent to the
initiation of the productive cycle. In addition, there is evidence to
suggest that viral enhancers may also facilitate viral DNA replication
by maintaining an open chromatin structure (33).
CMV enhancers, with the notable exception of the rat CMV enhancer
(42), contain multiple regulatory modules consisting of repeat and unique sequence elements (reviewed in reference
27). These regulatory modules, the repeat elements
in particular, frequently encompass consensus binding sites for a
variety of cellular transcription factors, including, for example,
binding sites for NF- While the significance of the enhancer for optimal expression of MIE
genes was long predicted from enhanced reporter gene expression in
transfection experiments, firm evidence of an amplifying function of
the mCMV enhancer in productive viral replication was provided only
recently by Angulo et al. (1), who demonstrated severely
impaired viral productivity of "enhancerless" mutants of mCMV.
Specifically, mCMV mutants with or without a stuffer sequence in place
of the enhancer were cloned as bacterial artificial chromosomes (BAC)
(29), and compared to parental or revertant mCMV, both
mutants were found to replicate with reduced efficacy upon transfection
of the respective BAC plasmids in permissive fibroblasts. Notably,
viral productivity was fully restored in mutants in which the mCMV
enhancer was replaced by the paralogous enhancer of hCMV. This study
has thus shown that species specificity of CMVs is not determined by
the enhancer and that the hCMV enhancer can substitute for the mCMV
enhancer, at least with regard to an optimal infection of permissive
fibroblasts in cell culture. The fact that enhancerless mutants were
capable of producing some progeny (1) demonstrates that the
enhancer is not essential for productive viral replication but performs
precisely the function indicated by its name: it enhances! The residual
infectivity is likely to be mediated by a basal activity of the
authentic mCMV MIEP, located at positions Virus replication in diverse cell types in vivo may be subject to
enhancer-directed regulation by transcription factors not implicated in
the permissive infection of fibroblasts in cell culture. Furthermore,
regulation may address the MIEP directly. In this article, we report on
the in vivo growth and organ distribution of recombinant virus
mCMVhMIEPE, in which the complete MIEPE of mCMV was replaced by the
paralogous core promoter and enhancer of hCMV.
(This paper will be part of the Ph.D. thesis of N. K. A. Grzimek at the Faculty of Biology of the
Eberhard-Karls-Universität, Tübingen, Germany.)
Construction of recombinant viruses.
For reasons of
biosafety, recombinants containing the hCMV MIEPE were based on an open
reading frame (ORF) m152 (38) immune evasion gene deletion
mutant (mCMV (i) Plasmid constructs for homologous recombination.
Recombinant plasmids were constructed according to established
procedures. Enzyme reactions were performed as recommended by the
suppliers. Specifically, plasmid pAMB25, containing the sequence from
map positions 176,441 to 187,035 of the mCMV Smith strain genome
(38) (GenBank accession no. MCU68299 [complete genome])
placed into the BamHI site of pACYC184 (16), was
used for construction of the MIEPE deletion plasmid pAMB25
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vivo Replication of Recombinant Murine
Cytomegalovirus Driven by the Paralogous Major Immediate-Early
Promoter-Enhancer of Human Cytomegalovirus
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
B (within 18-bp repeats), ATF/CREB (within
19-bp repeats), and RAR-RXR family members (reference
2; for an overview see reference
13). Since these transcription factors are involved
in signaling pathways, regulation at the enhancer has been implicated
in cell-type restricted and differentiation-dependent patterns of hCMV
MIE promoter-enhancer (MIEPE)-driven reporter gene expression in
transgenic in vivo mouse models during embryogenesis and in mature
tissues (5, 6, 20). Likewise, the enhancer is said to serve
as a genetic target element for reactivation of latent CMV by
extracellular signals (32), such as by tumor necrosis factor
alpha effected by NF-
B (37).
1 to
48 relative to the
ie1/3 transcription start site, which was spared in the
enhancerless mutants (1). In addition, promoter activity may
be enhanced by downstream sequences in the noncoding exon 1 of the
ie1/3 transcription unit that contains regulatory elements,
such as SP1 binding sites and CAAT boxes. Accordingly, enhancerless BAC
plasmids with an additional deletion of the promoter and downstream
sequences did not generate viable virus (1).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
orf152) of mCMV, strain Smith ATCC-VR194. Mutant
mCMV
orf152 and its revertant mCMVorf152-rev were generously provided
by U. H. Koszinowski and I. Crnkovic-Mertens, Max von Pettenkofer
Institute for Hygiene and Microbiology, Munich, Germany. In vivo
replication of mCMV
orf152 in genetically susceptible BALB/c
(H-2d) mice is comparable to that of parental
mCMV Smith or mCMVorf152-rev only after an immunoablative treatment by
total-body 137Cs
irradiation with a dose of at least 8 Gy, whereas replication is largely prevented by residual immunity after
immunoreductive treatment with doses of up to 6 Gy (not shown). For the
sake of brevity, mCMV
orf152 is herein referred to as mCMV, except
when its distinction from parental mCMV Smith is specifically required.
MIEPE
(Fig. 1A).
To construct a plasmid that
contains a deletion ranging from nucleotides
5 to
1272, counted
relative to the 5' start site of the ie1/3 transcription
unit corresponding to position 182,895 of the complete genome, pAMB25
was digested with MunI and MluI (cleavage
positions +209 and
2091, respectively). Surplus deletions of
downstream ie1/3 and ie2 sequences were restored
by PCR. Specifically, primer Nata-2
(5'-CAATGCATCTTAAGTACCGTCGCAGTCTTCGGTCTG-3', containing an AflII and a NsiI site) and primer Nata-7
(5'-CCGTCGCTTGTAATATCTGG-3') were used to amplify a 742-bp
fragment of the ie1/3 transcription unit. This fragment was
digested with NsiI and MluI. Primer Nata-1 (5'-CAATGCATGCGGCCGCGCAAATTAGGGGATTTCAGTGC-3',
containing a NotI and an NsiI site) and
primer Nata-8 (5'-AACAAGAGAGATCAGTCTCG-3') were used to
amplify a 1,433-bp fragment of the ie2 gene that included
the complete ie2 promoter. This fragment was digested with
MunI and NsiI and was ligated together with the
digested ie1/3 PCR fragment into MluI- and
MunI-cleaved pAMB25.

View larger version (36K):
[in a new window]
FIG. 1.
Construction and verification of recombinant viruses.
All map positions are given relative to the 5' start site (counted as
+1) of the ie1/3 transcription unit of mCMV, and
illustrations are drawn to scale. (A) Map of plasmid constructs for
homologous recombination. The HindIII physical map of
the mCMV Smith strain genome is shown at the top. For the construction
of the mCMV MIEPE deletion plasmid pAMB25
MIEPE, plasmid pAMB25 was
digested with MluI and MunI and surplus deletions
were restored by PCR, resulting in a final deletion of 1,267 bp
(
MIEPE). Arrows indicate the orientations of ie1/3 and
ie2 transcription. Plasmid phCMVMIEPE-gpt.lacZ
was generated by insertion of the hCMV enhancer and core promoter
(solid box, representing hCMV nucleotides
14 to
601 relative to the
start site of the hCMV ie1-ie2 transcription unit) and of a
gpt.lacZ reporter gene cassette flanked by loxP sites
(asterisks). (B) MIEPE swap mutants. Maps are shown on the left and the
corresponding HindIII cleavage analysis is shown on the
right. (Left) Expanded HindIII fragments K and L of the
mCMV Smith strain genome are shown on the top, illustrating the
location of the MIEPE and flanking ie sequences within the
authentic 7.1-kbp L fragment (map corresponding to lane 1). Replacement
of the mCMV MIEPE by the hCMV MIEPE (solid box) and insertion of a
gpt.lacZ reporter gene cassette flanked by loxP sites
(asterisks) created novel HindIII fragments of 0.8, 2.84, and 8.26 kbp in the genome of recombinant virus
mCMVhMIEPE-gpt.lacZ (map corresponding to lane 2). For the
generation of recombinant virus mCMVhMIEPE, the gpt-lacZ
cassette was removed from mCMVhMIEPE-gpt.lacZ via Cre
recombinase-mediated loxP-specific recombination, leaving a single loxP
site (asterisk) and generating a shortened HindIII L
fragment of 6.51 kbp (map corresponding to lane 3). (Right) Purified
virion DNA was subjected to cleavage by HindIII, and
fragments were analyzed by agarose gel electrophoresis, Southern blot,
and hybridization with MIEPE type-specific
-32P-end-labeled oligonucleotide probes. Lanes: M,
indicated size markers; 1, DNA of parental virus mCMV
orf152; 2, DNA
of mCMVhMIEPE-gpt.lacZ; 3, DNA of mCMVhMIEPE. Left panel,
ethidium bromide-stained gel; center panel, autoradiograph obtained
after hybridization of the Southern blot with the 30-bp probe
mE-oligo-P; right panel, autoradiograph obtained after stripping of the
same filter followed by hybridization with the 30-bp oligonucleotide
probe hE-oligo-P. See Fig. 3 for the map locations of the two probes.
14 to
601 relative to the transcription
start site of the ie1-ie2 transcription unit of hCMV. This
fragment was digested with NotI and AflII and was
inserted into NotI- and AflII-digested pAMB25
MIEPE. To facilitate further cloning procedures, phCMVMIEPE was cloned. Specifically, a 2.9-kbp AvrII fragment that
included the MIEPE of hCMV flanked by mCMV ie1/3 and
ie2 sequences was ligated into the XbaI site of
pUC19. For the final construction of phCMVMIEPE-gpt.lacZ,
phCMVMIEPE was partially digested with NruI (cleaving at
position
629 relative to the 5' transcription start site of mCMV
ie1/3), followed by digestion with NotI and ligation to the 5.3-kbp gpt.lacZ fragment flanked by loxP
sites. This marker gene cassette had been generated from plasmid plg1 (kindly provided by M. Messerle, Max von Pettenkofer Institute, Munich,
Germany) by XbaI cleavage, filling up of the sticky ends with Klenow DNA polymerase, and NotI cleavage. Throughout,
the fidelity of PCR-based cloning steps was verified by sequencing (automated DNA sequencing system, model 4000; LI-COR Inc., Lincoln, Nebr.).
(ii) Generation and purification of recombinant virus
mCMVhMIEPE-gpt.lacZ.
Recombinant viruses were
generated by homologous recombination in NIH 3T3 fibroblasts (no.
CL-163; American Type Culture Collection, Rockville, Md.) transfected
with plasmid DNA linearized by ScaI restriction enzyme
cleavage and infected with mCMV. Specifically, NIH 3T3 cells were
plated in six-well culture plates (catalog no. 3046; Falcon, Meylan
Cedex, France) and incubated under standard conditions (37°C, 5%
CO2, and humidified atmosphere) in Dulbecco's modified
Eagle's medium (DMEM) (catalog no. 4196-039; Gibco BRL, Eggenstein,
Germany) supplemented with 10% (vol/vol) fetal calf serum, 2 mM
L-glutamine, 100 U of penicillin per ml, and 0.1 mg of
streptomycin per ml. The next day, an average of 2 × 105 cells per monolayer were transfected with 2 µg of
phCMVMIEPE-gpt.lacZ DNA by using 10 µl of the nonliposomal
transfection reagent FuGENE 6 (catalog no. 1814443; Boehringer,
Mannheim, Germany). One day after transfection, cells were infected
under conditions of centrifugal enhancement of infectivity
(1,000 × g for 30 min at 20°C) at a multiplicity of
4 PFU* (centrifugal PFU) of sucrose-gradient-purified mCMV
(22). Excess virus was washed out, and cultures were refed with fresh DMEM. On day 2 after infection, the culture supernatant was
used for centrifugal infection of fetal mouse cells (usually, but
incorrectly, referred to as mouse embryo fibroblasts [MEF]) grown to
almost confluent monolayers in six-well culture plates. The infection
and subsequent cultivation was performed with selection medium MEM-S,
which is minimal essential medium (MEM) supplemented as specified
previously (40) and containing in addition 12.5 µg of
mycophenolic acid (catalog no. 11814-019; Gibco BRL) per ml and 100 µg of xanthine (catalog no. 1.08675.0050; Merck, Darmstadt, Germany)
per ml. After 3 days, that is, after plaques became visible, the
supernatant was harvested and used for a second round of recombinant virus selection and amplification on MEF. The supernatant thereof was
used to infect MEF centrifugally with a low multiplicity of ca. 0.02 PFU, corresponding to 0.4 PFU*. After 24 h, MEF were detached by
weak trypsinization, and cells infected with recombinant virus were
enriched by cytofluorometric cell sorting using the cell sorter
FACSort equipped with a cell concentrator module (Becton Dickinson, San
Jose, Calif.). CellQuest software (Becton Dickinson) was used for data
acquisition and processing. In brief, cells infected with recombinant
virus were identified by the lacZ reporter gene-encoded
intracellular
-galactosidase yielding a green 520-nm fluorescence
after FACS-Gal vital staining using fluorescein
di-
-D-galactopyranoside (FDG) (catalog no. F2756;
Sigma-Aldrich, Deisenhofen, Germany) as fluorogenic substrate. The
enzyme reaction was performed with 106 cells and 1 mM FDG
in a volume of 200 µl according to an established protocol
(12). Dead cells were excluded by propidium iodide staining,
and the electronic sort window was set on viable cells with high
fluorescein fluorescence (FL-1), discarding negative cells as well as
cells with low expression. Sorting was performed at a flow rate of ca.
2,000 cells/min and a sort rate of ca. 60 positive cells/min for a
total of ca. 5,000 cells sorted. Sorted cells were cocultivated with
MEF for 3 days in MEM-S. The supernatant was used to infect MEF at low
multiplicity for a second round of cytofluorometric sorting followed by
cocultivation. The final supernatant was used for limiting
dilution-based plaque purification on MEF monolayers, which was
performed by using an overlay of MEM-agarose (0.7% [wt/vol] agarose
in MEM with no phenol red) supplemented with Bluo-Gal (300 µg/ml
1) (catalog no. 15519-028; Gibco BRL) for blue
vital staining. Plaque-purified recombinant virus was propagated on MEF
and concentrated by sedimentation through a sucrose density cushion at
53,000 × g essentially as described previously
(22) except that the virus in the culture supernatant was
harvested after 3 days instead of after 5 days to minimize
contamination by cellular DNA. The infectious titer was determined by a
standard 4-day PFU assay on MEF with no centrifugal enhancement and was
2 × 108 PFU per ml for the particular batch used here.
(iii) Generation of recombinant virus mCMVhMIEPE. The gpt-lacZ cassette was removed from recombinant virus mCMVhMIEPE-gpt-lacZ via loxP-specific recombination by using Cre recombinase (3) introduced by the replication-defective adenovirus vector Cre-Ad (generously provided by W. H. Burns, Medical College of Wisconsin, Milwaukee, Wis.). Specifically, ca. 5 × 106 MEF grown to monolayer in a 10-cm-diameter petri dish were coinfected with mCMVhMIEPE-gpt.lacZ and Cre-Ad at multiplicities of infection of 0.02 PFU and 10 PFU equivalents, respectively. On day 2 after coinfection, that is, when plaques became visible, 20 µl of culture supernatant was used for infection of STO cells (mouse fibroblast cell line) (no. CRL-1503; ATCC), which are resistant to 6-thioguanine. Infected STO cells were cultured in six-well plates in DMEM supplemented with 5% (vol/vol) fetal calf serum and with 20 µg of 6-thioguanine (2-amino-6-methyl-mercaptopurine) (catalog no. A9546; Sigma) per ml for selection against gpt-expressing virus mCMVhMIEPE-gpt.lacZ. On day 4, supernatant of the infected STO cells was used for limiting dilution-based plaque purification on MEF covered by MEM-Bluo-Gal agarose. Unstained "white" plaques were recovered, and recombinant virus mCMVhMIEPE was propagated on MEF and purified by sucrose gradient ultracentrifugation. The titer of the virus batch used in the reported experiments was 1.7 × 108 PFU per ml.
Southern blot analysis of recombinant MIEPE regions.
Virion
DNA was prepared from the sucrose-gradient-purified virus stocks of
supernatant mCMV and of the recombinants as described previously
(22). Purified DNA was then subjected to a
HindIII restriction enzyme cleavage performed according
to established procedures. Fragments were separated on a 0.7% (wt/vol)
agarose gel, stained with ethidium bromide, and visualized by 302-nm UV illumination. After Southern transfer, consecutive hybridizations were
performed with fragment-specific,
-32P-end-labeled
oligonucleotide probes mE-oligo-P
(5'-AGGTAAGCCAATGGGTTTTTCCCATTACTG-3') and hE-oligo-P
(5'-TACATCTACGTATTAGTCATCGCTATTACC-3'), which are specific
for nonhomologous regions of the mCMV and hCMV enhancer, respectively
(for a map, see Fig. 3). After the first hybridization, the filter was
stripped, radioactivity was washed out, and the same filter was
rehybridized with the second probe. Specific bands were visualized by autoradiography.
Determination of genome-to-infectivity ratios.
Viral genomes
were quantitated essentially as described previously (references
22 and 44 and with modifications
described in reference 21) by serial dilution of
purified virion DNA prepared from stocks of known virus infectivity
titer, followed by mCMV ie1 gene exon 4-specific PCR,
Southern dot blot hybridization, and phosphorimaging. Specifically, the
-32P-end-labeled oligonucleotide IE1.2135 (4)
was used as the hybridization probe to visualize the specific 363-bp
amplificate, and plasmid pIE111 (28), which includes the
ie1 gene, was titrated as a standard. Infectivity measured
in terms of noncentrifugal PFU was related to the number of genomes.
For the infection of MEF with the parental mCMV Smith strain, a
genome-to-PFU ratio of ca. 500:1 had likewise been determined
previously (22).
Infection of immunocompromised mice.
Female BALB/c mice (8 weeks old) were severely immunocompromised by hematoablative total-body
irradiation with a single dose of 8 Gy delivered by a
137Cs source. In the absence of infection, this dose by
itself is 100% lethal within 14 days. At ca. 8 h after the
irradiation, recipients were infected intravenously in the tail vein
with 104 PFU of sucrose-gradient-purified virus (see above)
contained in 0.1 ml of physiological saline. Analyses were usually
performed on day 9 after infection, that is, at a prefinal stage of
multiple-organ CMV disease (36).
MIEPE-specific two-color in situ hybridization. The in vivo replication of viruses in host tissues is visualized by in situ hybridization (ISH) detecting the viral DNA that is accumulated in an intranuclear inclusion body during the late phase of the viral replication cycle. mCMV containing the authentic mCMV MIEPE and the recombinant virus mCMVhMIEPE, in which the mCMV MIEPE is replaced by the MIEPE of hCMV, are distinguished by MIEPE-specific polynucleotide probes (see Fig. 3), marked with a red and black label, respectively. Tissue was fixed in 4% (vol/vol) formalin buffered at pH 7.4 and was embedded in paraffin according to established procedures. Deparaffinized 2-µm sections of tissue were subjected to digestion with proteinase K (catalog no. P0390; Sigma), washed, dehydrated, and immersed with hybridization solution consisting of hybridization buffer (HybriBuffer ISH, catalog no. R012.050; Biognostik, Göttingen, Germany) and 1 µg of the respective DNA probes per ml. After denaturation for 10 min at 93°C, hybridization was performed for 16 h at 32°C. The MIEPE-specific staining was performed as specified in more detail below. Sections were counterstained for 5 s with hematoxylin to visualize the nuclei of uninfected cells. Microscopic analysis and documentation were made with a Zeiss research microscope (Axiophot; Carl Zeiss Jena GmbH, Jena, Germany) using oil-immersion optics (plan-Neofluar; Zeiss) for all magnifications.
(i) Single-color ISH specific for the mCMV MIEPE.
A red
label is used to visualize viral genomes containing the authentic MIEPE
of mCMV. The hybridization probe mMIEPE-P spans positions +1 to
597
(598 bps) within the mCMV MIEPE relative to the 5' transcription start
site of the MIE (ie1/3) transcription unit (see Fig. 3). The
probe was synthesized by PCR using plasmid pAMB25 as the template and
oligonucleotides Nata-9 (5'-CGGTACCGACGCTGGTCGCGCCTCTTAT-3') and Nata-10 (5'-TGGTCGCGCCTCTTATACCCACGTAGAA-3') as
forward and reverse primers, respectively. Labeling was achieved by
incorporation of fluorescein-conjugated dUTP (fluorescein-12-dUTP,
catalog no. 1373242; Boehringer Mannheim). The staining was performed
by using alkaline phosphatase-conjugated anti-fluorescein antibody
(catalog no. 1426338, Boehringer Mannheim) and new fuchsin as the
substrate, yielding a brilliant red color.
(ii) Single-color ISH specific for the hCMV MIEPE.
A black
label is used to visualize recombinant mCMV genomes carrying the
paralogous MIEPE of hCMV. The hybridization probe hMIEPE-P spans
positions
5 to
643 (638 bps) encompassing the inserted hCMV MIEPE
relative to the 5' transcription start site of the mCMV MIE
(ie1/3) transcription unit (see Fig. 3). The probe was
synthesized by PCR using plasmid pcDNA3 as the template and oligonucleotides Nata-3 and Nata-4 (specified above), respectively, as
forward and reverse primers. Labeling was achieved by incorporation of
digoxigenin (DIG)-11-dUTP (catalog no. 1093088; Boehringer Mannheim).
The staining was performed by using peroxidase-conjugated anti-DIG
antibody (catalog no. 1207733; Boehringer Mannheim) and diaminobenzidine tetrahydrochloride (catalog no. D-5637; Sigma) as the
substrate. The staining was enhanced by ammonium nickel sulfate
hexahydrate (catalog no. 09885; Fluka, Neu-Ulm, Germany), yielding a
black precipitate.
(iii) Two-color ISH for the simultaneous detection of mCMV and recombinant mCMVhMIEPE. Viruses mCMV (red label) and mCMVhMIEPE (black label) were detected simultaneously by two-color ISH in tissues of mice coinfected with both viruses. For hybridization, 1 ml of hybridization buffer contained 1 µg of each probe. The antibodies directed against fluorescein and DIG (see above) were added as a mixture for 1 h. The new fuchsin substrate for red staining was added before the enzyme reaction and enhancement for black staining were performed. Comparable sensitivity of the two MIEPE-specific hybridization probes was verified in tissues infected with either mCMV or mCMVhMIEPE by comparing the number of infected cells detected by the respective probe with the number of infected cells detected in the same tissues by using a previously published mixture of digoxigenized plasmids containing HindIII fragments A, I, and K, thereby representing 51.2 kbp of the mCMV genome (36).
IHC detection of the IE1 protein. The expression of the mCMV ie1 gene-encoded intranuclear IE1 protein pp89 (19) in mouse tissues was analyzed by immunohistochemical (IHC) staining. Paraffin sections (2 µm) were dewaxed in xylene. Sections were incubated for 15 min at 37°C in trypsin solution (1.25 mg/ml). Endogenous peroxidase was inactivated by an incubation for 30 min at 20°C in 0.5% (vol/vol) hydrogen peroxide in a 1:1 mixture of methanol and phosphate-buffered saline (PBS). Unspecific antibody binding sites were blocked with a 1:10 dilution of normal rabbit serum in PBS for 20 min at 20°C. The sections were then labeled for 60 min at 37°C with the IE1-specific monoclonal antibody CROMA 101 (mouse immunoglobulin isotype G1 [IgG1]). Mouse IgG1 (catalog no. X-0931; Dako, Hamburg, Germany) was used for the isotype control. The staining was performed by the ABC method, by using a biotinylated goat anti-mouse IgG-Fab antibody (catalog no. B0529; Sigma) at a 1:200 dilution in PBS for 30 min, followed by detection with an avidin-biotin-peroxidase complex (Vectastain ABC kit standard PK-4000) and diaminobenzidine tetrahydrochloride as the substrate. The staining was enhanced by ammonium nickel sulfate hexahydrate, yielding a black precipitate. Counterstaining of the sections was performed for 5 s with hematoxylin to visualize uninfected nuclei.
Area morphometry for quantitating multistep virus replication in tissue. Diapositives (Fujichrome 64T-RTP 135 for color transparencies; Fuji, Tokyo, Japan) of microphotographs taken from stained histological sections were scanned for computing (35-mm film desktop scanner LS-1000; Nikon, Tokyo, Japan). The extension of virus foci in tissue, specifically in the liver, was measured by using the area morphometry utility of the OPTIMAS 6.0 software for image analysis (Optimas Corporation, Bothell, Wash.).
| |
RESULTS |
|---|
|
|
|---|
Generation of recombinant virus mCMVhMIEPE.
The promoter of
the ie1/3 transcription unit of mCMV and the upstream
enhancer, that is, the complete MIEPE of mCMV, was replaced by the
paralogous MIE core promoter and enhancer of hCMV by homologous recombination. To avoid confusion, it must be recalled that the MIEPE
of hCMV controls the hCMV transcription unit ie1-ie2 and that the mCMV ie3 gene product IE3 (28) is the
main transactivator, corresponding to the hCMV ie2 gene
product IE2 (for overviews, see references 43 and
45). For selection by drug resistance and by
cytofluorometric cell sorting, recombinant virus
mCMVhMIEPE-gpt.lacZ was generated as an intermediate.
It should be noted that the promoter of mCMV gene ie2, which
is under the control of the same enhancer (30), was spared.
Gene ie2 is transcribed in a direction opposite to
ie1/3, leading to a 43-kDa protein specified by a spliced
1.75-kb mRNA (30). It has no direct counterpart in hCMV. Although ie2 proved to be nonessential for mCMV replication
in vitro and in vivo (8) and was hence used as a site for
integration of foreign genes into the mCMV genome (31), a
role for the IE2 protein in the biology of mCMV cannot be ruled out.
Thus, separating the enhancer from the promoter of ie2 by
the 5.3-kbp selection gene cassette might have an unpredictable
modulating function in viral pathogenicity. In addition, an influence
of the enzymes encoded by gpt and lacZ, namely
xanthine-guanine phosphoribosyl transferase and
-D-galactosidase, respectively, is difficult to assess.
To avoid all these unnecessary complications, gpt-lacZ was
removed by loxP-specific recombination to generate recombinant virus
mCMVhMIEPE, in which the hCMV enhancer is flanked upstream of
ie1/3 by the hCMV MIE core promoter and upstream of
ie2 by the authentic mCMV ie2 promoter (Fig. 1B;
resolved to greater detail in Fig. 3). As sketched in the map in Fig.
1B, the HindIII fragment L of mCMV is 7.1 kbp in size.
Insertions present in recombinant virus mCMVhMIEPE-gpt.lacZ
predict novel HindIII cleavage fragments of 0.8, 2.84, and 8.26 kbp. Replacement of the mCMV MIEPE by the shorter hCMV MIEPE
in recombinant virus mCMVhMIEPE predicts an altered
HindIII L fragment of 6.51 kbp. The
HindIII restriction enzyme cleavage patterns for
purified virion DNAs of the three viruses in fact revealed fragments of
the predicted sizes in the ethidium bromide-stained agarose gels (Fig.
1B, left panel). Their identity with the predicted fragments of 7.10 kbp (representing mCMV), 2.84 kbp (representing
mCMVhMIEPE-gpt.lacZ), and 6.51 kbp (representing mCMVhMIEPE)
was confirmed by Southern blotting and hybridization with the
enhancer-specific oligonucleotide probes (for map positions, see Fig.
3) mE-oligo-P (center panel) and hE-oligo-P (right panel).
The paralogous MIEPE of hCMV does not alter the in vitro
infectivity of mCMV in permissive mouse fibroblasts.
The capacity
of recombinant virus mCMVhMIEPE to infect murine fibroblasts in cell
culture was assessed in molecular terms by measuring the genome-to-PFU
ratio, that is, the number of viral genomes required for initiating a
cytolytic, plaque-forming productive infection. Since formation of a
plaque over 3 to 5 days in cell culture involves spread of the
infection, the genome-to-PFU ratio reflects viral infectivity under
multistep growth conditions. For the parental mCMV Smith strain ATCC
VR194/1981, a genome-to-PFU ratio of 500:1 has been determined
previously (22). That the mutant mCMVhMIEPE is not
significantly handicapped with respect to growth in cell culture was
already indicated by the comparable virus yields and plaque sizes
observed during the preparation of highly titratable stocks of purified
virions of mCMV
orf152 and recombinant mCMVhMIEPE derived therefrom
(not shown). For precise quantitation, virion DNA, corresponding to
defined infectivity measured as PFU, was isolated and titrated in
parallel to defined numbers of plasmids pIE111 encompassing gene
ie1 of mCMV that is shared by parental mCMV Smith,
mCMV
orf152, and mCMVhMIEPE. After PCR specific for a 363-bp sequence
located within exon 4 of gene ie1, a Southern dot blot in
microplate format was hybridized with a
-32P-end-labeled
internal oligonucleotide probe (Fig. 2,
top), and quantitation was performed by phosphorimaging (Fig. 2,
bottom). In essence, the previously published genome-to-PFU ratio of
500:1 (22) was reproduced here for mCMV Smith, and,
remarkably, the same result was obtained for virus mCMV
orf152
and even for mCMVhMIEPE.
|
Design of MIEPE-specific polynucleotide hybridization probes for two-color in situ detection of recombinant virus replication. In principle, an in vitro PFU assay performed by plating tissue homogenate onto permissive cell monolayers, such as MEF, could be used to get a relative estimate of in vivo virus replication. However, virus titers are not an absolute measure of virus replication in tissues because the efficacy of detection is unknown and may even differ between organs as a result of virus inactivation during the procedures. In addition, graphs of virus titers do not reveal the cell types infected in tissues, they do not verify the identity of the plaque-forming virus, and they fail to give an impression of the degree of tissue destruction. Specifically, virus titers do not distinguish between the number and the size of infectious foci in tissue. Thus, many small foci and a few large foci can give the same titer. While the number of foci can serve as a measure of the efficacy of virus dissemination to an organ and within an organ, the extension of an infectious focus in a particular tissue more directly reflects the capacity of a virus to grow in the cell types which constitute that tissue. A distinction between these two parameters appeared to us most informative. The detection and quantitation of infected cells in organs by in situ techniques is thus the superior method and was therefore our method of choice.
The difference between the viruses mCMV and mCMVhMIEPE is the nature of the MIEPE. Accordingly, a discrimination between infectious foci caused by these two viruses required MIEPE-specific DNA hybridization probes for two-color ISH detecting viral DNA. In the late phase of productive viral replication, viral DNA is found in the infected cells highly accumulated within an intranuclear inclusion body, that is, at the site of nucleocapsid assembly and DNA packaging. The high concentration of viral genomes in these inclusion bodies contributes to a high sensitivity of detection. The positions of the probes within the aligned hCMV and mCMV MIEPEs are delineated in Fig. 3, with homologous parts within 18- and 19-bp repeats shown in blue and green, respectively. It may be informative to note that our first approach had been to design mixtures of oligonucleotide probes directed selectively against nonhomologous interrepeat regions. However, even though principally successful, the low amount of label provided by an oligonucleotide required a long period of staining and thereby caused some unspecific background in uninfected tissue (not shown). It was a bit of a surprise that the sequence homologies between the two MIEPEs proved not to be critical for the specificity of the chosen polynucleotide hybridization probes mMIEPE-P and hMIEPE-P.
|
irradiation with a dose of 8 Gy and were infected
intravenously with either 104 PFU of mCMV or
104 PFU of mCMVhMIEPE or with a mixture (5 × 103 PFU plus 5 × 103 PFU) of both
viruses. At the time of clinically manifested severe CMV disease, that
is, usually on day 9 after infection, liver sections were stained for
single-color ISH with either probe mMIEPE-P (red label) specific for
mCMV or probe hMIEPE-P (black label) specific for recombinant virus
mCMVhMIEPE or were stained for two-color ISH with a mixture of both
probes. The results obtained with all possible combinations of viruses
and hybridization probes are shown in Fig.
4. The analysis of individual foci was
made possible by serial, neighboring sections, and in all instances a
central vein was chosen as a landmark in order to facilitate recognition of individual foci. The hybridizations document the exquisite specificity of the chosen probes. Thus, with probe mMIEPE-P, mCMV-derived foci appear red and mCMVhMIEPE-derived foci remain unstained (Fig. 4, top). In like manner, with probe hMIEPE-P, mCMV-derived foci remain unstained while mCMVhMIEPE-derived foci appear black (Fig. 4, center). Finally, by using a mixture of the two
probes, mCMV-derived and mCMVhMIEPE-derived foci are distinguished by
red and black staining, respectively (Fig. 4, bottom).
|
Recombinant virus mCMVhMIEPE and parental virus mCMV replicate independently. The presence of separate red and black foci in liver parenchyma (Fig. 4) already implied that mCMVhMIEPE does not depend on parental mCMV as a helper virus for replication in hepatocytes. This is even more elegantly revealed by an in situ single cell analysis as documented by serial sections tracking individual hepatocytes in a liver coinfected with mCMV and mCMVhMIEPE (Fig. 5). Probe mMIEPE-P stains mCMV-derived intranuclear inclusion bodies red. Out of many mCMV-infected cells present in the red focus, a single arrow highlights a hepatocyte with a prominent red-stained intranuclear inclusion body (Fig. 5A). A twin arrow points to a cell couple with clearly visible but only hematoxylin-stained intranuclear inclusion bodies, indicating the presence of a second focus apparently not caused by parental mCMV. The immediate neighbor in the series of sections, that is, only 2 µm from the first, was hybridized with probe hMIEPE-P (Fig. 5B). The twin arrow points to the very same cell couple seen before, but now black staining of their intranuclear inclusion bodies identifies them as hepatocytes being infected by mCMVhMIEPE, whereas the inclusion body of the hepatocyte in the left focus is no longer specifically stained. The third section in the series, 4 µm from the first, was hybridized with both probes (Fig. 5C). Although the mCMVhMIEPE-infected cell couple begins to disappear from sight, we can still recognize parts of the black-stained intranuclear inclusion bodies. Likewise, the mCMV-infected cell in the left focus can still be identified. In addition to the cells highlighted by the arrows, one can easily find many further examples of hepatocytes infected in a mutually exclusive manner by either mCMV or mCMVhMIEPE, some emerging and some disappearing in the section series.
|
The core promoter and enhancer swap does not impair the multistep
growth of mCMV in mouse liver parenchyma.
So far, the data have
documented that mCMV is principally capable of infecting mouse
hepatocytes in vivo after replacement of its complete autologous MIEPE
by the paralogous MIE core promoter and enhancer of hCMV. We next asked
whether a careful quantitative analysis would reveal any attenuation of
recombinant virus mCMVhMIEPE with respect to infection of hepatocytes.
It is instructive to recall the often-documented and generally accepted
experience that virus titers in tissues may differ markedly between
individual mice, even when mice are inbred and age matched and when all
experimental parameters are kept bona fide constant. Specifically,
after hematoablative treatment by
irradiation, titer variances
by a factor of 10 to 100 were not unusual for mCMV in organs, in
particular in the liver (40). The phenomenon has never been
investigated in detail, but since the genotoxic effect of radiation is
by its nature a stochastic event, differences in residual immune
functions are likely to be one significant cause of variance. Such
variances clearly complicate the approach of comparing the in vivo
infectivity of two viruses by comparing groups of mice infected with
either virus, and conclusions then always depend on a statistical
evaluation. However, there now exists a much better way: since we can
distinguish mCMV and recombinant mCMVhMIEPE in tissue by two-color ISH,
quantitative analysis can be made after coinfection of an animal so
that all parameters imposed by the individual recipient are absolutely the same for the two viruses being compared.
|
Evidence for attenuation of recombinant virus mCMVhMIEPE at extrahepatic sites. We next asked whether the results obtained for liver parenchyma, that is, for hepatocytes as its principal cellular constituent, would apply also to tissues composed of different cell types. The analysis was made by two-color ISH on day 9 after coinfection. The red- and black-stained cells, representing the replication of mCMV and mCMVhMIEPE, respectively, were counted for a representative area of tissue, and the results are presented as data pairs for five individual recipients (Fig. 6C). The analysis for the liver is included as a reference. Again, both viruses were found to have replicated with similar efficacy in the liver. There may be a tiny advantage for parental mCMV, as also seen in Fig. 6B, but in individual cases, such as in mouse 5, replication of mCMVhMIEPE predominates. By contrast, with no exception, there was an unequivocal replication advantage for parental mCMV in the spleen and the lungs of the same individual mice. Parental mCMV also predominated in the adrenal glands, with the exception of mouse 3, even though parental mCMV predominated in spleen and lungs of mouse 3. It must be noted, however, that colonization of adrenal glands by virus can be a random, clonal event. We even saw a case in which one of the paired adrenal glands was occupied by parental mCMV while its contralateral twin was occupied by mCMVhMIEPE (not shown). The molecular basis of the attenuation of mCMVhMIEPE is not yet known, and we wish to emphasize that we do not presently state that the foreign enhancer is responsible for a reduced replication in cell types other than hepatocytes. Our current impression is that mCMVhMIEPE has difficulty colonizing extrahepatic tissues although it is effectual in replicating within different tissues. One may speculate that mCMVhMIEPE is less efficient in breaking through endothelial barriers.
Recombinant virus mCMVhMIEPE is principally capable of infecting relevant target organs of CMV disease. Finally, we asked whether the paralogous MIEPE has an influence on organ tropism of mCMV in a qualitative sense. As we have shown previously, mCMV is a polytropic virus that productively infects many different cell types and thereby causes fatal multiple-organ histopathology, provided that controlling CD8 T cells are absent (36). This condition is fulfilled after the immunoablative treatment used in this study. The MIEPE governs the transcription of the ie1/3 transcription unit. One of the resultant proteins is IE1 (pp89), which is produced in large amounts, is located in the nucleus throughout the replicative cycle, and condenses during the late phase of the cycle in the intranuclear inclusion body. Thus, labeling of IE1 by IHC staining detects all infected cells and, unlike ISH, not just those that have reached the late phase. IE1-specific IHC detection performed with nickel-enhanced black staining is therefore the most sensitive method for documenting the full extent of infection in tissues. Mice were infected intravenously with recombinant virus mCMVhMIEPE, and replication in various organs was studied on day 9 (Fig. 7). Again, livers were found to be heavily infected (see panel A1 for overview and panels A2 and A3 for details). The focus resolved to greater detail in Fig. 7A2 nicely demonstrates a plaque-like character with a necrotic center of already lysed hepatocytes and a margin of more recently infected hepatocytes. Few infected endothelial cells can easily be distinguished from hepatocytes by much smaller size and by an elongated nucleus (panel A2, arrowhead). Infected Kupffer cells are rarely found after 8 Gy immunoablation. Note the prominent inclusion bodies in hepatocyte nuclei highlighted in Fig. 7A3. In addition, mCMVhMIEPE was found to replicate in perifollicular stromal cells of the spleen (panels B1 and B2) as well as in reticular stromal cells of the bone marrow (panel C). Among glandular tissues, adrenal gland medulla (panel D) and cortex (panel E) as well as salivary glands (panel F; shown are acini of the submandibular gland) proved to be target sites for the replication of mCMVhMIEPE. While only single glandular epithelial cells are infected in the salivary glands with no signs of a cytopathic effect, which is a known characteristic of persistent salivary gland infection (15), foci in adrenal cortex and medulla are in a highly advanced stage and are thus associated with extended tissue necrosis. This finding demonstrates that mCMVhMIEPE spreads very efficiently within adrenal gland cortical and medullary tissues, provided that the colonization of the organ was successful. Further target sites include the lungs (panel G), the heart muscle (panel H), and the digestive tract (panel J; shown is the gastric mucosa). In conclusion, recombinant virus mCMVhMIEPE infects all relevant target organs known before from the tissue distribution of the CMV Smith strain (36) and can cause the multiple-organ histopathology that is characteristic of full-blown CMV disease.
|
| |
DISCUSSION |
|---|
|
|
|---|
Previous work by Angulo et al. (1) has demonstrated that the MIE enhancer of hCMV can functionally replace the MIE enhancer of mCMV in mediating efficient productive infection of fibroblasts in cell culture by the respective recombinant virus. In that study, the authentic promoter of mCMV, including the TATA box, was spared. The data presented in this article fully confirm the previous results by an independent approach and extend them by providing an mCMV recombinant virus, namely mCMVhMIEPE, in which the promoter and enhancer of mCMV (that is, the complete MIEPE of mCMV) are replaced by the paralogous core promoter and enhancer of hCMV. For the sake of precision it should be mentioned that the enhancer or promoter-enhancer swap mutants are all based on deletion mutants of mCMV Smith. Mutants hMCMV-ES1 and -ES2 contain a deletion of an array of genes within HindIII fragment E' (1), namely, ORFs m151 to m158, whereas mCMVhMIEPE contains a deletion of ORF m152 only.
Our data contribute the following novel information. (i) Replacement of the mCMV MIEP by the hCMV MIE core promoter in addition to replacement of the enhancer does not affect the infectivity of mCMV in permissive murine fibroblasts in cell culture. (ii) The paralogous hCMV MIEPE in recombinant mCMVhMIEPE provides full support for productive mCMV replication in the mouse liver. (iii) The qualitative distribution of mCMV replication in differentiated tissues of adult mice is not determined by type-specific regulation operating at MIE enhancer or core promoter sequences.
Replacement of the MIEP.
Recombinant viruses mCMVhMIEPE (this
report) and hMCMV-ES1 and -ES2 (1) differ in that the ES
strains still contain the complete mCMV MIEP represented by the
sequence from positions
1 to
48 upstream of the 5' start site of
the mCMV ie1/3 transcription unit, whereas in mCMVhMIEPE,
the mCMV MIEP is deleted in total and is replaced by the hCMV MIE core
promoter starting with position
14 (relative to the hCMV
ie1-ie2 transcription start site) and including the TATA
box. Thus, the hCMV sequence 5'-GTTTAGTGAACCG-3' (positions
13 to
1) is not present in recombinant virus mCMVhMIEPE. This fact
has an important implication. Previous work has shown that this
sequence in the MIEP of hCMV contains a cis-acting, position-dependent repressor element (10, 23, 34) that
responds to autoregulation by the human IE2 protein. Notably, this
element is not present in the mCMV MIEP. Accordingly, human IE2 cannot repress the mCMV MIEPE (14). To our knowledge, it is not
known whether murine IE3 can substitute for human IE2 in addressing this repressor. However, since the sequence is knocked out in recombinant virus mCMVhMIEPE, this type of autoregulation is definitely not operative in cells infected with recombinant virus mCMVhMIEPE. Yet,
murine IE3 does exert an autoregulatory repression on the mCMV MIEPE
(28), although the target sequence has yet to be defined.
Thus, mCMV is subject to autoregulatory repression of its MIEPE by IE3,
while mCMVhMIEPE should be protected, and this difference should have
led to a difference in the replication efficacies. Contrary to existing
theory, however, mCMV and mCMVhMIEPE were found to replicate with the
same efficacy in vitro, namely, in permissive fibroblasts, as well as
in vivo, namely, in hepatocytes. We must hence assume that
autoregulatory repression of MIE gene expression by IE3 is operative in
both viruses, possibly by targeting a consensus motif in the enhancers,
or we must propose that replication efficacy is not influenced by
absence or presence of IE3-mediated repression.
13) and enhancer are sufficient for virus replication, whereas the
repressor module of the promoter is dispensable, at least in
fibroblasts in vitro and in hepatocytes in vivo.
Growth of mCMVhMIEPE in mouse liver parenchyma. That the hCMV enhancer can substitute for the mCMV enhancer for efficient replication in permissive, proliferating fibroblasts in cell culture was known previously (1) and has been confirmed in this study. It was open to question, however, whether this would apply in vivo to different cell types of different differentiation stages and in tissues in which cells are contact inhibited. Thus, regulation by cellular transcription factors, either activating or silencing the enhancer, may differ between different tissues and, in particular, may differ from the regulation in cultured fibroblasts. That this is not just a theoretical argument has been shown previously by meticulous studies on the tissue-specific activity of the hCMV MIEPE in transgenic mice expressing lacZ as reporter transgene under the control of the hCMV MIEPE during embryonal development and in mature tissues (5, 6, 20). It became very clear that the hCMV MIEPE is not pan-active in all cell types and during all developmental stages but is highly regulated, resulting in specific expression patterns of the transgene. It was hence concluded that the hCMV MIEPE is a critical control point for determining viral tropism in vivo. In adult mice, the reporter transgene was found to be expressed in many organs and in many cell types therein, including most known target tissues of hCMV replication during CMV disease in the human host (for an extensive list, see reference 6). Notable exceptions, surprisingly, included the liver in adult mice (6), even though CMV hepatitis is a common manifestation of CMV disease, with hepatocytes being undoubtedly the principal target cells of hCMV (35) and mCMV (reference 36 and this report) replication in the liver. Some hepatic expression of the transgene has been reported for embryofetal and neonatal liver (5, 20), suggesting that the activity of the hCMV MIEPE in the liver is dependent upon the developmental stage. However, the fetal liver is a site of extramedullary hematopoiesis, and the possibility that the reporter transgene was expressed in hematopoietic fetal liver cells instead of in hepatocytes was not ruled out in these studies. It should be noted, as can clearly be seen in the documented liver tissue sections, that infiltrates of hematopoietic origin were completely absent in the liver after the effective hematoablative treatment used in our model.
Silencing of the hCMV MIEPE in the murine liver is a recognized phenomenon and is actually causing problems in approaches to experimental in vivo gene therapy employing the hCMV MIEPE for expression of a transgene. Recent work has indicated that this enhancer silencing is associated with the absence of transcription factor NF-
B in adult mouse hepatocytes in vivo and that stimuli inducing
NF-
B can reactivate a previously silenced hCMV MIEPE (25). In this context, it is notable that the mCMV MIEPE
contains more NF-
B binding sites than does the hCMV MIEPE, and this
may confer to mCMV a higher resistance to NF-
B deficiency.
In view of these data, it was of interest to see whether the hCMV MIEPE
promotes the replication of recombinant virus mCMVhMIEPE in the mouse
liver parenchyma. The answer given unequivocally by our experiments is
yes, it does, and hepatocytes are identified by the histology as the
most prominent target cell type in the liver. The formation of
extended, plaque-like lesions in the liver parenchyma reflects lytic
infection of hepatocytes. Infected endothelial cells were also visible
in most sections, while infected Kupffer cells were rarely seen but did
exist. There was no significant difference between mCMV and mCMVhMIEPE
with respect to focus number and focus growth in the liver. It is thus
likely that cis- or trans-regulating elements of
mCMV specified outside of the MIEPE, and therefore not present in the
transgene systems discussed above, are responsible for the activity of
the MIEPE. Previous work by Sambucetti et al. has indicated that the
IE1 protein of hCMV can mediate an activation of the enhancer by
induction of NF-
B (41), and Liu and Stinski have shown
that tegument proteins of hCMV can enhance the activity of certain
promoters (24). Similar mechanisms might apply to mCMV. We
have not yet addressed the question of whether the infection or the
genotoxic stress associated with the hematoablative treatment lead to
an upregulation of NF-
B in the liver, but this is obviously an issue
for future experiments and may help to explain the difference from the
transgene expression models.
Implication of the MIEPE in tissue tropism of CMV. Disease caused by mCMV in the immunocompromised host is typically a fatal multiple-organ CMV disease characterized by viral hepatitis (36), splenitis (36), adrenalitis (36, 39), interstitial pneumonia (40), moderate carditis (36), gastritis-enterocolitis (36), and bone marrow aplasia caused by infection of bone marrow stromal cells (26). The salivary glands are not a site of histopathology, but few highly productive glandular epithelial cells of serous as well as of mucous acini account for long-persisting infection (15) relevant to CMV transmission. It was unclear whether this typical pattern of tissue tropism and histopathology could be reproduced with recombinant virus mCMVhMIEPE. At most of these sites, transgenic hCMV MIEPE is active, with the notable exceptions of liver (discussed above), lungs, and most parts of the gastrointestinal tract (6). Data documented herein have shown that recombinant virus mCMVhMIEPE replicates at all these tissue sites, including those at which transgenic hCMV MIEPE is silenced. Since hepatitis, pneumonitis, and gastritis-enterocolitis are among the most prominent manifestations of clinical CMV disease, results obtained with mCMVhMIEPE reflect CMV pathogenesis more closely than was predicted by the transgene models. Altogether, the paralogous MIEPE does not alter the tissue tropism of mCMV in a qualitative sense. The observed lower rate of replication of mCMVhMIEPE at the analyzed extrahepatic sites awaits further analysis.
Conclusion.
Collectively, our data have shown that the
complete MIEPE of mCMV can be replaced by the paralogous enhancer plus
core promoter of hCMV without a significant influence on the efficacy
of virus replication in fetal fibroblasts in vitro and, notably, in
hepatocytes in vivo. Furthermore, at least in a qualitative sense,
tissue tropism is not altered in the immunodepleted host. Thus,
productive infection of permissive cell types does not strictly depend
on MIEPE type-specific sequence elements. This is not a trivial finding in view of the fact that during evolutionary adaptation to the respective host species, mCMV MIEPE and hCMV MIEPE have evolved quite
different arrangements and numbers of regulatory modules. For example,
mCMV MIEPE is longer than hCMV MIEPE and contains more NF-
B but
fewer CREB/ATF binding sites, and further differences could be listed.
Our data do not say that regulation at the MIEPE is not involved in
replication efficacy and cell type tropism but may rather indicate that
these parameters of productive infection are largely addressed by the
conserved common elements. What then could have been the selective
pressure for the evolution of the differences? Most likely, the fate of
the virus species is not decided by its replication in the
immunocompromised host but rather by its smartness in dealing with the
hostile immune system, by establishing latency, and by awakening for
recurrence and horizontal transmision. The role of the MIEPE in these
aspects of CMV biology can be addressed in vivo with the mCMVhCMV MIEPE
swap mutants now available.
| |
ACKNOWLEDGMENTS |
|---|
We thank Ulrich H. Koszinowski, Max von Pettenkofer Institute,
Munich, Germany, for the permission to use recombinant virus mCMV
orf152, and William H. Burns, Medical College of Wisconsin, Milwaukee, Wis., for the permission to use adenovirus vector Cre-Ad. Stipan Jonjic, Medical Faculty of Rijeka, Croatia, helped by supplying monoclonal antibody CROMA 101. Maria Rapp, now at the Institute for
Anatomy, Johannes Gutenberg University, Mainz, Germany, made contributions in earlier stages of the project. Irena Crnkovic-Mertens, Martin Messerle, and Armin Saalmüller helped us by offering advice.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institute for Virology, Johannes Gutenberg University, Hochhaus am Augustusplatz, 55101 Mainz, Germany. Phone: 49-6131-173650. Fax: 49-6131-395604. E-mail: Matthias.Reddehase{at}uni-mainz.de.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Angulo, A.,
M. Messerle,
U. H. Koszinowski, and P. Ghazal.
1998.
Enhancer requirement for murine cytomegalovirus growth and genetic complementation by the human cytomegalovirus enhancer.
J. Virol.
72:8502-8509 |
| 2. |
Angulo, A.,
C. Suto,
R. A. Heyman, and P. Ghazal.
1996.
Characterization of the sequences of the human cytomegalovirus enhancer that mediate differential regulation by natural and synthetic retinoids.
Mol. Endocrinol.
10:781-793 |
| 3. | Anton, M., and F. L. Graham. 1995. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol. 69:4600-4606[Abstract]. |
| 4. |
Balthesen, M.,
M. Messerle, and M. J. Reddehase.
1993.
Lungs are a major organ site of cytomegalovirus latency and recurrence.
J. Virol.
67:5360-5366 |
| 5. | Baskar, J. F., P. P. Smith, G. S. Ciment, S. Hoffmann, C. Tucker, D. J. Tenney, A. M. Colberg-Poley, J. A. Nelson, and P. Ghazal. 1996. Developmental analysis of the cytomegalovirus enhancer in transgenic animals. J. Virol. 70:3215-3226[Abstract]. |
| 6. | Baskar, J. F., P. P. Smith, G. Nilaver, R. A. Jupp, S. Hoffmann, N. J. Peffer, D. J. Tenney, A. M. Colberg-Poley, P. Ghazal, and J. A. Nelson. 1996. The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J. Virol. 70:3207-3214[Abstract]. |
| 7. | Boshart, M., F. Weber, G. Jahn, K. Dorsch-Häsler, B. Fleckenstein, and W. Schaffner. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521-530[Medline]. |
| 8. | Cardin, R. D., G. B. Abenes, C. A. Stoddard, and E. S. Mocarski. 1995. Murine cytomegalovirus IE2, an activator of gene expression, is dispensable for growth and latency in mice. Virology 209:236-241[Medline]. |
| 9. |
Chang, Y. N.,
S. Crawford,
J. Stall,
D. R. Rawlins,
K. T. Jeang, and G. S. Hayward.
1990.
The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements.
J. Virol.
64:264-277 |
| 10. |
Cherrington, J. M.,
E. L. Khoury, and E. S. Mocarski.
1991.
Human cytomegalovirus ie2 negatively regulates gene expression via a short target sequence near the transcription start site.
J. Virol.
65:887-896 |
| 11. |
Dorsch-Häsler, K.,
G. M. Keil,
F. Weber,
M. Jasin,
W. Schaffner, and U. H. Koszinowski.
1985.
A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus.
Proc. Natl. Acad. Sci. USA
82:8325-8329 |
| 12. | Fiering, S. N., M. Roederer, G. P. Nolan, D. R. Micklem, D. R. Parks, and L. A. Herzenberg. 1991. Improved FACS-Gal: flow cytometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs. Cytometry 12:291-301[Medline]. |
| 13. | Ghazal, P., and J. A. Nelson. 1993. Transcription factors and viral regulatory proteins as potential mediators of human cytomegalovirus pathogenesis, p. 360-383. In Y. Becker, G. Darai, and E. S. Huang (ed.), Molecular aspects of human cytomegalovirus diseases Springer-Verlag Publishers, Heidelberg, Germany. |
| 14. |
Hermiston, T. W.,
C. L. Malone, and M. F. Stinski.
1990.
Human cytomegalovirus immediate-early 2 protein region involved in negative regulation of the major immediate-early promoter.
J. Virol.
64:3532-3536 |
| 15. |
Jonjic, S.,
W. Mutter,
F. Weiland,
M. J. Reddehase, and U. H. Koszinowski.
1989.
Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes.
J. Exp. Med.
169:1199-1212 |
| 16. |
Keil, G. M.,
A. Ebeling-Keil, and U. H. Koszinowski.
1984.
Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection.
J. Virol.
50:784-795 |
| 17. |
Keil, G. M.,
A. Ebeling-Keil, and U. H. Koszinowski.
1987.
Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products.
J. Virol.
61:526-533 |
| 18. |
Keil, G. M.,
A. Ebeling-Keil, and U. H. Koszinowski.
1987.
Sequence and structural organization of murine cytomegalovirus immediate-early gene 1.
J. Virol.
61:1901-1908 |
| 19. |
Keil, G. M.,
M. R. Fibi, and U. H. Koszinowski.
1985.
Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus.
J. Virol.
54:422-428 |
| 20. | Koedood, M., A. Fichtel, P. Meier, and P. J. Mitchell. 1995. Human cytomegalovirus (HCMV) immediate-early enhancer/promoter specificity during embryogenesis defines target tissues of congenital HCMV infection. J. Virol. 69:2194-2207[Abstract]. |
| 21. |
Kurz, S. K.,
M. Rapp,
H.-P. Steffens,
N. K. A. Grzimek,
S. Schmalz, and M. J. Reddehase.
1999.
Focal transcriptional activity of murine cytomegalovirus during latency in the lungs.
J. Virol.
73:482-494 |
| 22. | Kurz, S., H.-P. Steffens, A. Mayer, J. R. Harris, and M. J. Reddehase. 1997. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J. Virol. 71:2980-2987[Abstract]. |
| 23. |
Liu, B.,
T. W. Hermiston, and M. F. Stinski.
1991.
A cis-acting element in the major immediate-early (IE) promoter of human cytomegalovirus is required for negative regulation by IE2.
J. Virol.
65:897-903 |
| 24. |
Liu, B., and M. F. Stinski.
1992.
Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements.
J. Virol.
66:4434-4444 |
| 25. |
Löser, P.,
G. S. Jennings,
M. Strauss, and V. Sandig.
1998.
Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NF B.
J. Virol.
72:180-190 |
| 26. | Mayer, A., J. Podlech, S. Kurz, H.-P. Steffens, S. Maiberger, K. Thalmeier, P. Angele, L. Dreher, and M. J. Reddehase. 1997. Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes. J. Virol. 71:4589-4598[Abstract]. |
| 27. | Meier, J. L., and M. F. Stinski. 1996. Regulation of human cytomegalovirus immediate-early gene expression. Intervirology 39:331-342[Medline]. |
| 28. |
Messerle, M.,
B. Bühler,
G. M. Keil, and U. H. Koszinowski.
1992.
Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3.
J. Virol.
66:27-36 |
| 29. |
Messerle, M.,
I. Crnkovic,
W. Hammerschmidt,
H. Ziegler, and U. H. Koszinowski.
1997.
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome.
Proc. Natl. Acad. Sci. USA
94:14759-14763 |
| 30. |
Messerle, M.,
G. M. Keil, and U. H. Koszinowski.
1991.
Structure and expression of murine cytomegalovirus immediate-early gene 2.
J. Virol.
65:1638-1643 |
| 31. | Mocarski, E. S., G. B. Abenes, W. C. Manning, L. C. Sambucetti, and J. M. Cherrington. 1990. Molecular genetic analysis of cytomegalovirus gene regulation in growth, persistence and latency. Curr. Top. Microbiol. Immunol. 154:47-74[Medline]. |
| 32. | Nelson, J. A., J. W. Gnann, Jr., and P. Ghazal. 1990. Regulation and tissue-specific expression of human cytomegalovirus. Curr. Top. Microbiol. Immunol. 154:75-100[Medline]. |
| 33. |
Nelson, J. A., and M. Groudine.
1986.
Transcriptional regulation of the human cytomegalovirus major immediate-early gene is associated with induction of DNase I-hypersensitive sites.
Mol. Cell. Biol.
6:452-461 |
| 34. |
Pizzorno, M. C., and G. S. Hayward.
1990.
The IE2 gene products of human cytomegalovirus specifically down-regulate expression from the major immediate-early promoter through a target sequence located near the cap site.
J. Virol.
64:6154-6165 |
| 35. | Plachter, B., C. Sinzger, and G. Jahn. 1996. Cell types involved in replication and distribution of human cytomegalovirus. Adv. Virus Res. 46:195-261[Medline]. |
| 36. | Podlech, J., R. Holtappels, N. Wirtz, H.-P. Steffens, and M. J. Reddehase. 1998. Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J. Gen. Virol. 79:2099-2104[Abstract]. |
| 37. |
Prösch, S.,
K. Staak,
J. Stein,
C. Liebenthal,
T. Stamminger,
H.-D. Volk, and D. H. Krüger.
1995.
Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNF is mediated via induction of NF- B.
Virology
208:197-206[Medline].
|
| 38. | Rawlinson, W. D., H. E. Farrell, and B. G. Barrell. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70:8833-8849[Abstract]. |
| 39. |
Reddehase, M. J.,
S. Jonjic,
F. Weiland,
W. Mutter, and U. H. Koszinowski.
1988.
Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors.
J. Virol.
62:1061-1065 |
| 40. |
Reddehase, M. J.,
F. Weiland,
K. Münch,
S. Jonjic,
A. Lüske, and U. H. Koszinowski.
1985.
Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs.
J. Virol.
55:264-273 |
| 41. | Sambucetti, L. C., J. M. Cherrington, G. W. Wilkinson, and E. S. Mocarski. 1989. NF-kappaB activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 8:4251-4258[Medline]. |
| 42. | Sandford, G. R., and W. H. Burns. 1996. Rat cytomegalovirus has a unique immediate early gene enhancer. Virology 222:310-317[Medline]. |
| 43. | Spector, D. H. 1996. Activation and regulation of human cytomegalovirus early genes. Intervirology 39:361-377[Medline]. |
| 44. |
Steffens, H.-P.,
S. Kurz,
R. Holtappels, and M. J. Reddehase.
1998.
Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.
J. Virol.
72:1797-1804 |
| 45. | Stenberg, R. M. 1996. The human cytomegalovirus major immediate-early gene. Intervirology 39:343-349[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»